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Abstract: 
Background: High-sensitivity cardiac troponin (hs-cTn) elevations are 
associated with incident cardiovascular disease events in primary prevention
samples. However, the mechanisms underlying this association remain 
unclear. 
Methods: We studied 458 men without known cardiovascular disease who 
participated in the cardiovascular disease sub-study of the Multicenter AIDS 
Cohort Study and had cardiac CT angiography. We used multivariable linear 
and logistic regression models to examine the cross-sectional associations 
between coronary artery stenosis, coronary artery plaque, indexed left 
ventricular mass (LVMi), and the outcome of hs-cTnI. We also evaluated the 
associations between HIV serostatus or use of highly active antiretroviral 
therapy (HAART) and hs-cTnI. 
Results: The mean age was 54 years, 54% were White, and 61% were HIV-
infected. In multivariable-adjusted logistic models, comparing the highest 
quartile of LVMi with the lowest quartile, the odds ratio of hs-cTnI ≥ 75th 
percentile was 2.36 (95% confidence interval 1.11 to 5.13). There was no 
significant association between coronary stenosis severity or plaque type 
and hs-cTnI in linear models; however, in logistic regression models coronary
artery stenosis ≥ 70% (8% of sample) was associated with a higher 
likelihood (OR 3.08) of having hs-cTnI ≥ 75th percentile. There were no 
associations between HIV serostatus or HAART use and hs-cTnI in either 
linear or logistic models. 
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Conclusion: Among primary prevention men with or at risk for HIV, hs-cTnI 
levels were strongly associated with LVMi but were not associated with HIV 
infection or treatment status, or with coronary plaque-type or stenosis until 
the extremes of severity (≥ 70% stenosis). 
Abstract word count: 248
Key words: high-sensitivity troponin; coronary disease; left ventricular 
hypertrophy; cardiac computed tomography 
Abbreviations: HAART = highly active antiretroviral treatment; LVMi = 
indexed left ventricular mass; hs-cTn = high-sensitivity cardiac troponin; 
CVD = cardiovascular disease
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Introduction: 
With the advent of highly active antiretroviral therapy (HAART), the 
lifespan of HIV-infected persons is approaching that of the general 
population.1 As a result, HIV-infected persons increasingly are diagnosed with
chronic age-related non-communicable diseases such as cardiovascular 
disease (CVD). By age 60, the cumulative CVD incidence has been estimated
as 21% in men and 14% in women with HIV infection, compared with 13% 
and 9%, respectively, in the US general population.2,3 HIV infection is 
associated with chronic inflammation, endothelial dysfunction, platelet 
activation and coagulopathy; as well as a higher prevalence of CVD risk 
factors such as diabetes, hypertension and dyslipidemia.2,4 The use of HAART
may in some circumstances further exacerbate dyslipidemia, diabetes and 
endothelial dysfunction,4,5 and increase the risk of CVD events.6 These 
findings all highlight the importance of recognizing the increased CVD risk 
among HIV-infected adults. 
High-sensitivity cardiac troponin (hs-cTnI) has been identified as a 
novel circulating biomarker of subclinical myocardial damage in 
asymptomatic adults with no prior history of CVD.7,8 Greater levels of hs-cTn 
are strongly and independently associated with future risk for heart failure, 
CVD death and all-cause mortality in primary prevention cohorts.9-12 
However, it is unclear whether hs-cTn elevation reflects primarily subclinical 
ischemia from occult coronary artery disease, structural heart disease (such 
as left ventricular hypertrophy, LVH), or a combination of both. Given the 
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potential future use of hs-cTn as a biomarker of risk in the primary 
prevention setting10 and as a surrogate marker for cardiovascular health,12 it 
is important to better understand the underlying mechanisms of hs-cTn 
elevation in adults without known CVD. Improved understanding of such 
mechanisms may be achieved by evaluating the relationship between hs-cTn
and abnormalities detected using cardiac computed tomography 
angiography (CCTA). However, few if any rigorously conducted prospective 
cohorts of primary prevention adults without known CVD have high-quality 
CCTA data available.
In addition, while an association of HIV infection with increased 
subclinical coronary atherosclerosis as measured using cardiac CT has been 
previously shown,13,14 much less is known about the association between HIV 
and myocardial damage as measured by hs-cTn.13 Therefore, using cross-
sectional data from a cohort of men without known CVD, with or at risk for 
HIV, from the Multicenter AIDS Cohort Study (MACS), we sought to examine 
associations of hs-cTnI with left ventricular mass indexed to body surface 
area (LVMi) or with coronary anatomy (both measured by CCTA). As a 
secondary analysis, we assessed whether HIV serostatus modifies these 
associations. 
Methods:  
MACS is a prospective cohort study that enrolled HIV-infected and 
uninfected men who had sex with men.15 A total of 6972 participants were 
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enrolled in Baltimore, Chicago, Pittsburgh, and Los Angeles during three time
periods: 1984 to 1985, 1987 to 1991, and 2001 to 2003. The MACS 
cardiovascular sub-study included MACS participants who underwent CCTA 
imaging between January 2010 and June 2013 (n= 759).14 Participants were 
between 40 to 70 years of age, weighed less than 300 pounds, and had no 
prior coronary artery bypass graft or valve surgery, or prior history of 
coronary angioplasty. Participants were excluded if they had atrial 
fibrillation, intravenous contrast allergy, or chronic kidney disease with 
estimated glomerular filtration rate < 60 ml/min/m2 using the Modification of 
Diet in Renal Disease equation within 30 days of the CT scan. For the present
analyses, we also excluded participants reporting any history of CVD events 
(n=3) and those without available stored blood specimens for hs-cTnI testing
(n=298). Men remaining for analysis (n=458) had cardiac CT imaging and 
hs-cTnI blood samples drawn on the same day. 
MACS participants were seen every 6 months for standardized interviews, 
physical examination, and blood and urine collection. Baseline characteristics
included in the current analysis were collected at the preceding MACS study 
visit closest to CT scanning. Body mass index was calculated as weight in 
kilograms divided by height in meters squared. Current smoking was self-
reported. Hypertension was defined as blood pressure > 140/90 mmHg or 
use of antihypertensive medications with a self-reported history of 
hypertension. Diabetes was defined as fasting glucose ≥ 126 mg/dL or use of
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insulin or oral hypoglycemic agents. Total and high-density lipoprotein 
cholesterol, and triglycerides were measured after a 12 hour fast. The 
Friedewald equation was used to estimate low-density lipoprotein 
cholesterol.  HIV parameters collected included plasma HIV RNA levels, CD4 
T-lymphocyte cell counts (cells/µL), type of antiretroviral therapy (ART) used 
and ART duration of exposure in years, as well as history of AIDS-defining 
malignancy or opportunistic infection. 
Participants in the MACS-CVD study underwent a non-contrast CT to assess 
coronary artery calcium (CAC). If patients met eligibility criteria (see Online 
Supplement) a contrast-enhanced CCTA was performed using a 64-slice 
multi-detector scanner at three centers and a 320-slice CT scanner at the 
fourth center (Johns Hopkins Hospital).16 A heart rate target of between 50-
65 bpm was achieved using oral and/or intravenous beta-blockers or calcium
channel blockers as required. CT scans were read centrally at the Los 
Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. 
Coronary plaque was assessed and measured in each of the modified 15 
coronary segments outlined by the American Heart Association.17 Plaque 
severity was subjectively graded: 0 = no plaque, 1 = mild plaque, 2 = 
moderate plaque, or 3 = severe plaque. For each reported segment of 
stenosis, the most narrowed diameter was graded between 0 to 4 according 
to percent stenosis severity: 0 = no plaque/no stenosis, 1 = 1-29%, 2 = 30-
49%, 3 = 50-69%, or 4 = greater than 70% stenoses. Each plaque was also 
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assessed as calcified, noncalcified, or mixed (less than 50% area of plaque 
calcified). CAC scores were calculated using the method of Agatston.18 
Measurements of the anteroinferior and septal-lateral diameters in the short-
axis planes at the left ventricular mid-papillary level, and four-chamber long-
axis left ventricular cavity lengths were obtained. These measurements were
used to calculate left ventricular mass as previously described.19 We defined 
LVH as an LVMi ≥ 96 g/m2 (not including papillary muscles), based on 
previous studies.20
Hs-cTnI was measured from samples collected on the same day as CT 
imaging using the ARCHITECT STAT high sensitive Troponin I assay (Abbott 
Laboratories’, Abbott Park, IL). The 99th% (upper reference limit) for this 
assay is 34.2 ng/L for males, 15.6 ng/L for females and 26.2 ng/L for all 
healthy adults in the general population overall. The limit of detection (LOD) 
for this assay is 1.2 ng/L with a coefficient of variation <10% at 4.7 ng/L. 
Baseline characteristics were compared between participants according to 
quartiles of hs-cTnI using chi-square for categorical and t-testing for 
continuous variables. Due to a non-normal distribution, we analyzed hs-cTnI 
levels as a loge-transformed continuous outcome variable and as a 
categorical outcome variable (≥ 75th percentile or < 75th percentile of the 
overall sample distribution). We then tested the association of LVMi, 
coronary artery stenosis severity, and type of coronary artery plaque 
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(calcified, non-calcified and mixed) with the outcome of hs-cTnI using 
multivariable linear and logistic regressions. We tested LVMi as a continuous 
exposure variable, categorized in quartiles, and dichotomized as LVH vs no 
LVH. We subsequently evaluated if HIV serostatus and HAART use were 
associated with hs-cTnI levels. Finally, we determined whether the 
associations of LVMi, coronary artery stenosis and coronary artery plaque 
with hs-cTnI levels are modified by HIV serostatus (positive or negative). 
We used hierarchical 4 models with progressive adjustment for covariates. 
Model 1 adjusted for age (years), race (white, African American, Hispanic, or 
other), education and study site (Baltimore, Chicago, Pittsburgh, Los 
Angeles); model 2 further adjusted for BMI (kg/m2), smoking status (never, 
former, current), smoking pack/year, and alcohol (never, low-moderate, 
moderate-heavy, hazardous use); model 3 further adjusted for systolic BP 
(mmHg), anti-hypertensive medication use (yes/no), diabetes medication use
(yes/no), levels of total cholesterol (mg/dL), high-density lipoprotein 
cholesterol (mg/dL), triglycerides (mg/dL), C-reactive protein (mg/L), and use
of lipid lowering medications (yes/no); model 4 also adjusted for HIV 
serostatus (positive or negative). Finally, model 5 adjusted for LVH (< 96 g/
m2 or ≥ 96 g/m2) in analyses with coronary artery stenosis as exposure and 
adjusted for coronary artery stenosis (< 70% or ≥ 70%) for analyses with 
LVMi as exposure. We considered a 2-sided p < 0.05 as statistically 
significant. 
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Results: 
Baseline characteristics of the study participants are presented in 
Table 1. Men with the uppermost hs-cTnI quartile had higher body mass 
index, higher systolic BP, and were more likely to be African American or 
using diabetes medication than men in the lower quartiles. They were also 
more likely to have LVH and greater coronary artery stenosis severity on 
CCTA imaging, without significant differences in plaque composition. There 
were no differences in the crude proportion of men with HIV within each of 
the hs-cTnI quartiles.
When left ventricular mass was modeled as a categorical exposure by 
quartile, the outcome of log-transformed hs-cTnI was higher in the fourth 
LVMi quartile compared to men in the first LVMi quartile (adjusted beta-
coefficient 0.30, 95% confidence interval [CI] 0.11 to 0.49) (Table 2). No 
significant difference in hs-cTnI was seen between men with and without 
LVH, although the confidence intervals were wide and the number of 
participants with LVH by this criterion was small (n=9). In logistic regression 
models, the odds ratio for the outcome of hs-cTnI ≥ 75th percentile was 2.36 
(95% CI 1.11 to 5.13) in the fourth LVMi quartile compared with the first 
quartile (Figure 1, Supplemental Table 1). Although the association 
between LVMi quartiles and odds of troponin ≥ 75th percentile 
(Supplemental Table 2) appeared stronger (OR 6.28; 95% CI 1.52 to 
31.04, comparing 4th to 1st quartile of LVMi) in HIV-uninfected men than in 
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HIV-infected men (OR 1.33; 95% CI 0.47 to 3.78), there was no evidence of 
statistical interaction for this comparison (p=0.36). 
We also examined the relationship between exposure categories of 
coronary stenosis severity and hs-cTnI as an outcome. In multivariable linear 
regression analyses with log-transformed troponin level as a continuous 
outcome variable, there was no significant association between hs-cTnI and 
severity of coronary artery stenoses (Tables 2 and 3). However, with hs-
cTnI modeled as a binary outcome, the odds ratio of having hs-cTnI ≥75th 
percentile was 3.08 (95% CI 1.23 to 7.74) among men with coronary artery 
stenosis ≥70% even after adjustment for baseline left ventricular 
hypertrophy (Supplemental Table 1). Hs-cTnI levels were not associated 
with prevalence of any coronary plaque or type of plaque (Table 2). There 
was also no association between troponin levels with coronary plaque when 
stratified by HIV serostatus (Supplemental Table 2). 
Finally, we evaluated the relationship of HIV-specific variables, 
including HIV serostatus and HAART therapy, with hs-cTnI as the outcome. 
There were no significant differences in hs-cTnI levels between HIV-infected 
and uninfected men (Table 4 and Supplementary Table 3). Among HIV-
infected participants, there were also no differences in hs-cTnI level between
those receiving or not receiving HAART, and between HAART that did or did 
not include protease inhibitors. 
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Discussion: 
The current study adds to our understanding of the association 
between abnormalities in cardiac anatomy, visualized using CCTA imaging, 
and high-sensitivity troponin levels in a well-characterized primary 
prevention cohort of HIV-infected and uninfected men. We also extend prior 
research by further assessing the relationship between HIV clinical 
parameters and hs-cTn levels. First, we demonstrate that higher LVMi is 
associated with subclinical myocardial damage, as indicated by hs-cTnI, 
among men without known CVD even after adjusting for severity of coronary 
artery disease. We were unable to adequately assess associations between 
LVH (as defined by a cutoff LVM of ≥ 96 g/m2) and since there were very few 
cases with LVH in the MACS-CVD cohort. Abnormalities in coronary luminal 
anatomy appeared to be less convincingly associated with elevated hs-cTnI 
levels in the primary prevention sample, though we did find an association 
with hs-cTnI in the small subgroup (~8%) with coronary artery stenoses ≥ 
70%, which are typically considered clinically flow limiting.21 Second, 
presence of coronary plaque or plaque type among men with coronary 
atherosclerosis were not associated with hs-cTnI levels in our study, a result 
that appears to contradict prior findings.22 Third, we found no association 
between HIV serostatus and hs-cTnI levels and, although power may have 
been limited to detect weak associations, there was also no association with 
use and duration of HAART (or with ART drug class). 
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Troponin levels have been traditionally considered a diagnostic marker
for acute myocardial infarction. The recent use of high-sensitivity, over 
standard, troponin assays has helped identify asymptomatic adults without 
known CVD at increased risk of future adverse CVD outcomes outside of the 
acute coronary syndrome setting. For example, in the Dallas Heart Study, 
after a median follow-up of 6.4 years, all-cause mortality was 1.9% in 
participants with undetectable hs-cTnT levels in comparison to 28.4% among
those with hs-cTnT ≥ 14 ng/L.9 Similar findings of worse cardiovascular 
outcomes among persons with abnormal hs-cTn levels have been reported in
multiple other cohorts of persons without known CVD.23 
However, the mechanisms underlying this association have been 
unclear. In the Dallas Heart Study, age, male sex, black race, left ventricular 
mass and wall thickness by MRI were associated with detectable hs-cTnT, but
no independent associations between hs-cTnT and prior history of 
myocardial infarction or angina, coronary artery calcium, or left ventricular 
ejection fraction were seen.9 However, to our knowledge, none of the primary
prevention cohorts that have previously studied the determinants of hs-cTn 
abnormalities had CT angiography imaging information on coronary artery 
disease and stenosis severity. Hence, it remains poorly understood whether 
the presence of elevated high-sensitivity troponin levels in adults without 
known CVD is due to underlying coronary artery disease, to structural heart 
disease (e.g., higher LVMi reflecting severity of ventricular hypertrophy), or a
mix of both. Our results demonstrate that higher LVMi appears more 
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consistently associated with elevated hs-cTnI in populations than subclinical 
coronary artery disease in primary prevention populations. Because 
individuals with the highest LVMi are particularly at risk of subclinical 
myocardial damage, persons without known CVD who are found to have an 
elevation in hs-cTn may benefit from investigation for structural heart 
disease (noting that obstructive CAD is also rare in this population). It is 
unclear if these individuals may also benefit from certain interventions such 
as more intensive BP reduction to reduce long-term risk.24  
In a small subgroup (<10%) of our sample with overtly asymptomatic 
though potentially flow limiting coronary stenoses ≥70%, we also found 
elevated hs-cTnI levels and, as such, careful questioning regarding exercise 
capacity and chest pain status also appears indicated among adults without 
known CVD with elevated hs-cTn. Elevated hs-cTn levels have previously 
been associated with subclinical CAD (as determined by coronary artery 
calcium measured using non-contrast cardiac CT) in individuals without 
known coronary artery disease.25 However this finding has been inconsistent 
and coronary artery calcium imaging does not any provide information 
regarding stenosis severity or burden of non-calcified atherosclerosis in the 
coronary bed.9 
To our knowledge, this is the first study to examine the association 
between coronary artery disease measured using a more sensitive imaging 
modality, contrast-enhanced CCTA, and hs-cTn levels among adults without 
known CVD. Prior analyses evaluating associations between CCTA findings 
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and hs-cTn levels have involved mainly small studies of patients with 
symptomatic coronary artery disease (typically stable chest pain) who were 
evaluated clinically using CCTA. In symptomatic patients, hs-cTn levels have 
been associated with coronary artery disease and severity of stenosis, and, 
using intravascular ultrasound, have also been associated with total non-
calcified plaque and the presence of vulnerable plaque features like positive 
remodeling or thin-cap fibroatheroma.26,27 Our study of men without known 
CVD would suggest that the associations between coronary disease and hs-
cTn levels are weaker in persons without symptoms and that, in primary 
prevention, the main driver linking hs-cTn level abnormalities to adverse 
outcomes appears to be structural heart disease. This consideration is critical
in our understanding of using hs-cTn level as a marker of myocardial health 
in primary prevention and as a possible surrogate outcome in clinical 
studies.28 
In addition to providing a unique opportunity to explore associations of 
cardiac structure and coronary anatomy with hs-cTnI levels among men 
without known CVD, our study also allowed for further assessment of the 
association between HIV clinical factors and hs-cTnI. HIV-infected persons 
have a greater prevalence of traditional CVD risk factors and an increased 
risk of CVD events.2,3 Asymptomatic HIV-infected  persons also have an 
increased prevalence of subclinical atherosclerosis with more calcified and, 
particularly, more non-calcified coronary artery plaque compared with HIV-
uninfected individuals.14 In addition, HIV-infected persons appear to have a 
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higher prevalence of vulnerable plaque that is associated with increased risk 
of CVD events.29 
Previously, it has been unclear if hs-cTn levels may differ between HIV-
infected and uninfected persons. Fitch et al. found an association between 
HIV infection and hs-cTn level abnormalities in a single center study of 225 
asymptomatic participants, with an association apparent between hs-cTnT 
levels and coronary plaque presence among HIV-infected (n=155) but not 
HIV-uninfected participants (n=70).13 However, the sample size was small 
with limited adjustment for potential confounders. In our larger, multi-center 
study with more rigorous adjustment for covariates, there was no association
of hs-cTnI levels with any or type of coronary artery plaque among HIV-
infected men. There were also no associations apparent between hs-cTnI 
levels and HIV serostatus, HAART presence/duration, or types of HAART. The 
Fitch study and our study also differed in hsTn assays and control group 
characteristics. Larger studies, perhaps combining data from multiple 
cohorts, may provide more definitive data on the relationship between HIV 
infection and hs-cTn levels. 
The strengths of our study include a diverse community-based 
population of men without known CVD, rigorous ascertainment of covariates,
measurement of hs-cTnI levels at the same time as CCTA images were 
acquired, and the inclusion of broad representation of both HIV-infected and 
uninfected male participants. However, there are some limitations. The 
limited number of cases may constrain the statistical power of our analyses 
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to evaluate for interactions with hs-cTn levels, particularly regarding null 
findings for stenoses >50%, plaque type and HIV exposures. MACS 
participants are men and our findings may not be representative of women 
with or without HIV infection.2 While ~40% of this sample was not HIV-
infected (but were at risk for HIV), our results may not be generalizable to all 
persons without known CVD in the community. Further, our sample consisted
of a heterogenous mix of men with and without HIV. We do not see this as a 
major limitation; however, as most observational cohorts contain mixes of 
demographic features (e.g. diabetics and non-diabetics) and we adjusted for 
HIV status in our models. Indeed, we are not aware of another large cohort of
primary prevention adults who have both CCTA and hs-cTn data available 
and, hence, needed to leverage this particular cohort to probe the potential 
anatomical mechanisms underlying subclinical hs-cTn elevation in primary 
prevention adults. Troponin levels are known to be affected by renal 
function,30 and we cannot generalize our findings to those with renal disease 
given participants with an estimated glomerular filtration rate < 60 
ml/min/1.73m2 were excluded. Other limitations include the observational 
study design, which cannot rule out residual confounding as a factor in any 
associations reported.  
In our cohort of HIV-infected and uninfected men without known CVD, 
we found that asymptomatic individuals with elevated hs-cTnI levels were 
more likely to have increased LVMi and that hs-cTnI levels appeared less 
associated with coronary artery disease or plaque-type, except in the small 
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subgroup of approximately 8% of men with luminal stenosis ≥70%. These 
findings were apparent in both HIV-infected and uninfected men. The 
presence of HIV infection itself, nor HIV disease clinical control status nor 
HAART treatment, did not appear to be associated with hs-cTnI levels in our 
study. These findings corroborate prior knowledge that abnormalities in hs-
cTn levels among adults without known CVD are more strongly tied to 
structural heart disease than to coronary artery stenosis. 
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Figure 1. Odds ratios and 95% confidence intervals for elevated 
troponin levels (high-sensitivity troponin I ≥ 75th percentile) 
according to degree of coronary artery stenosis, presence of 
coronary plaque, indexed left ventricular mass quartiles, and HIV 
status. Multivariable-adjustment for age, race, education, center, body mass
index, smoking status, pack years smoked, alcohol intake, systolic blood 
pressure, anti-hypertensive medication use, diabetes medication use, C-
reactive protein, total cholesterol, high-density lipoprotein cholesterol, 
triglycerides, and use of lipid lowering medications. LVMi = indexed left 
ventricular mass 
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Table 1. Characteristics of participants by troponin levels at the visit closest to CT scan
Characteristic Overall
High-sensitivity troponin I (ng/L)  
1st Quartile 2nd Quartile 3rd Quartile 4th Quartile p-value(0.2-1.7) (1.8-2.3) (2.4-3.6) (3.7-51.9)
n 458 124 117 106 111
Age (year) 53.6 (7.1) 52.2 (6.3) 53.9 (7.7) 54.1 (7.2) 54.4 (7.2) 0.07
Race (%) 0.003
   White 248 (54.1) 71 (57.3) 65 (55.6) 63 (59.4) 49 (44.1)
   African American 141 (30.8) 27 (21.8) 32 (27.4) 32 (30.2) 50 (45.0)
    Hispanic or other 69 (15.1) 26 (21.0) 20 (17.1) 11 (10.4) 12 (10.8)
Education level 0.83
   High school or less 103 (22.5) 29 (23.4) 20 (17.1) 25 (23.6) 29 (26.1)
   At least 1 y of college 128 (27.9) 39 (31.5) 36 (30.8) 27 (25.5) 26 (23.4)
   Undergraduate degree 93 (20.3) 23 (18.5) 24 (20.5) 23 (21.7) 23 (20.7)
   Graduate degree 134 (29.3) 33 (26.6) 37 (31.6) 31 (29.2) 33 (29.7)
Study sites 0.04
   Baltimore 192 (41.9) 47 (37.9) 42 (35.9) 52 (49.1) 51 (45.9)
   Chicago 29 (6.3) 5 (4.0) 4 (3.4) 9 (8.5) 11 (9.9)
   Pittsburgh 32 (7.0) 6 (4.8) 10 (8.5) 8 (7.5) 8 (7.2)
   Los Angeles 205 (44.8) 66 (53.2) 61 (52.1) 37 (34.9) 41 (36.9)
Tobacco use 0.24
   Never 111 (24.2) 37 (29.8) 31 (26.5) 21 (19.8) 22 (19.8)
   Former 230 (50.2) 58 (46.8) 62 (53.0) 57 (53.8) 53 (47.7)
   Current 117 (25.5) 29 (23.4) 24 (20.5) 28 (26.4) 36 (32.4)
Cumulative pack-years    
3.8 [0.0, 






   Never 101 (22.1) 30 (24.2) 18 (15.4) 26 (24.5) 27 (24.3)
   Low-moderate 282 (61.6) 73 (58.9) 74 (63.2) 65 (61.3) 70 (63.1)
   Moderate-heavy 52 (11.4) 12 (9.7) 19 (16.2) 11 (10.4) 10 (9.0)
   Hazardous use 23 (5.0) 9 (7.3) 6 (5.1) 4 (3.8) 4 (3.6)
Number of drinks/wk   0.4 [0.2, 3.5] 0.4 [0.2, 1.5] 1.5 [0.2, 3.5] 0.3 [0.2, 1.5] 0.3 [0.2, 1.5] 0.17
Body mass index (kg/m2) 26.6 (4.5) 25.1 (3.3) 26.6 (4.7) 27.2 (4.6) 27.5 (5.0) 0.001
Systolic blood pressure (mmHg) 126 (15) 121 (12) 123 (13) 129 (16) 130 (15) 0.001
Total cholesterol (mg/dL) 189.5 (37.9) 186.8 (40.1) 192.1 (35.9) 190.6 (39.6) 188.6 (36.1) 0.72
HDL-C (mg/dL) 49.6 (15.1) 51.5 (16.0) 48.7 (13.5) 48.0 (13.0) 50.1 (17.2) 0.30
LDL-C (mg/dL) 112.0 (34.7) 108.3 (36.3) 114.7 (32.9) 114.2 (36.8) 111.3 (32.8) 0.47
Triglyceride level (mg/dL) 119 [85, 173] 122 [83, 170] 125 [84, 183]
119 [92, 
171] 108 [82, 171] 0.75
Statin use (%) 136 (31.9) 37 (31.6) 34 (31.5) 29 (30.2) 36 (34.3) 0.94
C-reactive protein 1.1 [0.6, 2.4] 0.9 [0.5, 1.7] 1.5 [0.8, 2.6] 1.0 [0.5, 2.0] 1.2 [0.5, 3.0] 0.002
Hypertension medication use 
(%) 146 (31.9) 31 (25.0) 35 (29.9) 40 (37.7) 40 (36.0) 0.14
Diabetes medications (%) 36 (7.9) 10 (8.1) 3 (2.6) 9 (8.7) 14 (12.6) 0.05
Lipid medications (%) 155 (34.4) 40 (32.8) 40 (34.8) 34 (33.0) 41 (36.9) 0.91
HIV-infected (%) 278 (60.7) 77 (62.1) 71 (60.7) 66 (62.3) 64 (57.7) 0.89
Persons with detectable HIV 
RNA‡ 224 (82.4) 59 (79.7) 64 (91.4) 51 (79.7) 50 (78.1) 0.14
CD4+ T-cell count nadir 
(cells/mm3)
334.8 
(202.3) 346.9 (194.1) 296.9 (197.8)
365.8 
(209.0) 331.0 (207.8) 0.24
HAART experienced (%) 0.95
   Protease inhibitor use 57 (12.4) 12 (9.7) 14 (12.0) 14 (13.2) 17 (15.3)
   NNRTI use 36 (7.9) 10 (8.1) 9 (7.7) 9 (8.5) 8 (7.2)
   Other 185 (40.4) 55 (44.4) 48 (41.0) 43 (40.6) 39 (35.1)
Stenosis ≥ 50% 73 (16.3) 13 (10.5) 23 (20.0) 11 (10.8) 26 (24.1) 0.01
Stenosis ≥ 70% 34 (7.6) 4 (3.3) 11 (9.6) 3 (2.9) 16 (14.8) 0.002
Coronary artery disease 0.02
   stenosis <30% 290 (63.3) 90 (72.6) 66 (56.4) 70 (66.0) 64 (57.7)
   30% ≤stenosis <50% 95 (20.7) 21 (16.9) 28 (23.9) 25 (23.6) 21 (18.9)
   stenosis ≥50% 73 (15.9) 13 (10.5) 23 (19.7) 11 (10.4) 26 (23.4)
Coronary plaque prevalence
   Any coronary plaque 343 (74.9) 89 (71.8) 86 (73.5) 80 (75.5) 88 (79.3) 0.59
   Non-calcified plaque 272 (59.4) 67 (54.0) 71 (60.7) 69 (65.1) 65 (58.6) 0.39
   Mixed plaque 165 (36.0) 42 (33.9) 42 (35.9) 33 (31.0) 48 (43.2) 0.28
   Calcified plaque 172 (37.6) 41 (33.1) 43 (36.8) 38 (35.8) 50 (45.0) 0.27
Left ventricular hypertrophy† 
(%) 9 (2.0) 1 (0.8) 0 (0) 5(5.0) 3(2.8) 0.05
Data are mean (SD), median [interquartile range] or number (percentage).
* Low - moderate (1-2 drinks/day or 3-4 drinks/day for no more than once a month); Moderate - heavy (3-4 drinks/day for more than 
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once a month or ≥5 drinks/day for less than once a month); Hazardous use (≥5 drinks/day for at least once a month).
† Left ventricular hypertrophy defined as ≥ 96g/m2
‡ Detectable considered ≥ 50 copies/ml, proportion is of HIV infected participants
HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; HIV = human immunodeficiency virus; 
HAART = highly active antiretroviral therapy; NNRTI = non-nucleoside reverse transcriptase inhibitor
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Table 2. The association of high-sensitivity troponin I levels with coronary artery stenosis and indexed left ventricular mass 
  N Model 1 Model 2 Model 3 Model 4 Model 5
Stenosis category 1
   Stenosis < 50% 376 Ref Ref Ref Ref Ref
   Stenosis ≥ 50% 73 0.12 (-0.05, 0.29) 0.11 (-0.06, 0.28) 0.08 (-0.09, 0.26) 0.08 (-0.10, 0.26) 0.06 (-0.12, 0.24)
Stenosis category 2
   Stenosis < 70% 414 Ref Ref Ref Ref Ref
   Stenosis ≥ 70% 34 0.19 (-0.04, 0.42) 0.19 (-0.04, 0.42) 0.18 (-0.07, 0.42) 0.18 (-0.06, 0.43) 0.15 (-0.10, 0.40)
Stenosis category 3
   Stenosis < 30% 290 Ref Ref Ref Ref Ref
   30% ≤ Stenosis < 50% 95 -0.03 (-0.18, 0.13) -0.04 (-0.19, 0.12) -0.002 (-0.16, 0.16) -0.01 (-0.17,0.15)
-0.04 (-0.20, 0.12)
   Stenosis ≥ 50% 73 0.11 (-0.06, 0.29) 0.10 (-0.07, 0.27) 0.08 (-0.10, 0.27) 0.08 (-0.10, 0.26) 0.05 (-0.13, 0.24)
Presence of any coronary plaque
   No 115 Ref Ref Ref Ref
   Yes 343 0.04 (-0.11, 0.18) -0.01 (-0.16, 0.14) -0.03 (-0.19, 0.12) -0.04 (-0.20,0.11)
Presence of non-calcified plaque
   No 186 Ref Ref Ref Ref
   Yes 272 0.02 (-0.10, 0.15) -0.003 (-0.13, 0.12) -0.02 (-0.14, 0.11) -0.02 (-0.15, 0.11)
Presence of mixed plaque
   No 293 Ref Ref Ref Ref
   Yes 165 0.03 (-0.11, 0.16) 0.02 (-0.11, 0.15) 0.03 (-0.10, 0.17) 0.03 (-0.10, 0.17)
Presence of calcified plaque
   No 286 Ref Ref Ref Ref
   Yes 172 0.07 (-0.06, 0.21) 0.05 (-0.08, 0.18) 0.05 (-0.08, 0.19) 0.06 (-0.08, 0.19)
Structural heart disease
   Indexed LV mass < 96 g/m2 432 Ref Ref Ref Ref Ref
   Indexed LV mass ≥ 96 g/m2 9 0.39 (-0.05, 0.83) 0.39 (-0.05, 0.82) 0.29 (-0.15, 0.73) 0.28 (-0.16, 0.72) 0.33 (-0.13, 0.80)
Continuous indexed LV mass 441 0.01 (0.01, 0.02) 0.01 (0.01, 0.01) 0.01 (0.00, 0.01) 0.01 (0.00, 0.01) 0.01 (0.01, 0.01)
Indexed LV mass* 
   Quartile 1 (23.7, 46.7) 108 Ref Ref Ref Ref Ref
   Quartile 2 (46.7, 54.4) 110 0.08 (-0.10, 0.26) 0.08 (-0.09, 0.26) 0.05 (-0.13, 0.23) 0.05 (-0.13, 0.23) 0.04 (-0.14, 0.23)
   Quartile 3 (54.4, 63.6) 112 0.28 (0.10, 0.45) 0.26 (0.08, 0.44) 0.21 (0.03, 0.40) 0.21 (0.03, 0.40) 0.21 (0.03, 0.40)
   Quartile 4 (63.6, 120.4) 111 0.40 (0.22, 0.58) 0.37 (0.20, 0.55) 0.29 (0.11, 0.48) 0.29 (0.10, 0.48) 0.30 (0.11, 0.49)
Assessed using multivariable linear regression
Model 1: Adjusted for age, race, education, and center. 
Model 2: Further adjusted for body mass index, smoking status, smoking pack/year, and alcohol intake. 
Model 3: Further adjusted for systolic blood pressure, anti-hypertensive medication use, diabetes medication use, C-reactive protein, total cholesterol, high-
density lipoprotein cholesterol, triglycerides, and use of lipid lowering medications.
Model 4: Further adjusted for human immunodeficiency virus infection status. 
Page 27 of 30
Model 5: Stenosis further adjusted for left ventricular hypertrophy (indexed LV mass ≥ 96 g/m2), and structural heart models further adjusted for stenosis (<70% 
or ≥70%). 
* quartile parameters indicated in parenthesis in g/m2
LV = left ventricular  
Table 3. The association of high-sensitivity troponin I levels with coronary artery stenosis and indexed left ventricular mass by
HIV serostatus 
    HIV-infected HIV-uninfected
  N Model 1 Model 2 Model 3 N Model 1 Model 2 Model 3
Stenosis categories 1
          Stenosis < 50% 229 Ref Ref Ref 147 Ref Ref Ref
          Stenosis ≥ 50% 42 0.12 (-0.08, 0.33) 0.13 (-0.07, 0.34) 0.10 (-0.11, 0.32) 31 0.10 (-0.19, 0.40) 0.01 (-0.29, 0.32) 0.05 (-0.29, 0.38)
Stenosis categories 2
          Stenosis < 70% 252 Ref Ref Ref 162 Ref Ref Ref
          Stenosis ≥ 70% 18 0.27 (-0.03, 0.57) 0.29 (-0.01, 0.58) 0.33 (0.02, 0.65) 16 0.11 (-0.27, 0.49) 0.02 (-0.36, 0.40) 0.07 (-0.35, 0.49)
Stenosis categories 2
          Stenosis < 30% 168 Ref Ref Ref 122 Ref Ref Ref
          30% ≤ Stenosis < 50% 68 0.01 (-0.18, 0.19) 0.02 (-0.16, 0.19) 0.07 (-0.11, 0.25) 27 0.01 (-0.30, 0.32) -0.07 (-0.39, 0.24) -0.03 (-0.36, 0.30)
          Stenosis ≥ 50% 42 0.13 (-0.09, 0.34) 0.14 (-0.07, 0.35) 0.13 (-0.09, 0.36) 31 0.11 (-0.19, 0.41) 0.001 (-0.31,0.31) 0.04 (-0.30, 0.39)
Presence of any coronary plaque
          No 64 Ref Ref Ref 51 Ref Ref Ref
          Yes 214 0.06 (-0.12, 0.25) 0.01 (-0.17, 0.19) -0.01 (-0.19, 0.17)
129 0.07 (-0.18, 0.33) -0.01 (-0.27, 0.26) 0.01 (-0.27, 0.29)
Presence of non-calcified plaque
          No 102 Ref Ref Ref
84 Ref Ref Ref
          Yes 176 0.03 (-0.13, 0.19) -0.04 (-0.20, 0.11) -0.06 (-0.22, 0.10)
96 0.08 (-0.14, 0.29) 0.07 (-0.14, 0.29) 0.09 (-0.14, 0.33)
Presence of mixed plaque
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          No 179 Ref Ref Ref
114 Ref Ref Ref
          Yes 99 -0.02 (-0.18, 0.13) -0.002 (-0.16, 0.15) 0.03 (-0.13, 0.18) 66 0.15 (-0.09, 0.39) 0.12 (-0.12, 0.36) 0.12 (-0.15, 0.38)
Presence of calcified plaque
          No 181 Ref Ref Ref
105 Ref Ref Ref
          Yes 97 0.04 (-0.12, 0.19) 0.02 (-0.14, 0.18) 0.02 (-0.15, 0.18) 75 0.14 (-0.11, 0.39) 0.09 (-0.16, 0.34) 0.12 (-0.15, 0.39)
Structural heart disease
          LV mass < 96 g/m2 259 Ref Ref Ref 173 Ref Ref Ref
          LV mass ≥ 96 g/m2 8 0.42 (-0.01, 0.86) 0.42 (-0.004, 0.84) 0.31 (-0.11, 0.74) 1 -0.30 (-1.78, 1.18)  -0.38 (-1.87,1.10)
 -0.42 (-1.93,
1.09)
Continuous indexed LV mass 441 0.01 (0.00, 0.01) 0.01 (0.00, 0.01) 0.01 (0.00, 0.01) 0.02 (0.01, 0.03) 0.02 (0.01, 0.02) 0.02 (0.01, 0.03)
Indexed LV mass* 
          Quartile 1 [23.7, 46.7] 65 Ref Ref Ref 43 Ref Ref Ref
          Quartile 2 [46.7, 54.4] 71 0.03 (-0.19, 0.24) 0.04 (-0.17, 0.25) 0.01 (-0.21, 0.22) 39 0.19 (-0.13, 0.50) 0.16 (-0.16, 0.48) 0.22 (-0.13, 0.56)
          Quartile 3 [54.4, 63.6] 62 0.24 (0.02, 0.47) 0.23 (0.01, 0.46) 0.17 (-0.06, 0.40) 50 0.33 (0.03, 0.63) 0.29 (-0.01, 0.59) 0.33 (0.01, 0.65)
          Quartile 4 [63.6, 120.4] 69 0.30 (0.09, 0.52) 0.27 (0.06, 0.48) 0.20 (-0.03, 0.42) 42 0.56 (0.24, 0.87) 0.47 (0.15, 0.80) 0.47 (0.10, 0.83)
Model 1: Adjusted for age, race, education, and center. 
Model 2: Further adjusted for body mass index, smoking status, smoking pack/year, and alcohol intake. 
Model 3: Further adjusted for systolic blood pressure, anti-hypertensive medication use, diabetes medication use, C-reactive protein, total cholesterol, high-density lipoprotein 
cholesterol, triglycerides, and use of lipid lowering medications.
* quartile parameters indicated in parenthesis in g/m2
LV = left ventricular  
Table 4. The association of high-sensitivity troponin I levels with HIV treatment variables 
  N Model 1 Model 2 Model 3
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HAART in HIV-infected men
          HIV-uninfected 180 Ref Ref Ref






















Model 1: Adjusted for age, race, education, and center. 
Model 2: Further adjusted for body mass index, smoking status, smoking pack/year, and alcohol intake.
Model 3: Further adjusted for systolic blood press, anti-hypertensive medication use, diabetes medication use, C-reactive 
protein, total cholesterol, high-density lipoprotein cholesterol, triglycerides, and use of lipid lowering medications. *Further 
adjusted for CD4+ (on HAART).
HAART = high active antiretroviral therapy; 
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